Last reviewed 2026-04-23 · How we verify

Prednisone+Cytarabine+vincristine+Mercaptopurine

Prednisone+Cytarabine+vincristine+Mercaptopurine is a Combination chemotherapy regimen Small molecule drug developed by Shanghai Children's Medical Center. It is currently in Phase 3 development for Acute lymphoblastic leukemia (ALL) in pediatric patients.

This combination chemotherapy regimen suppresses leukemic cell proliferation through multiple mechanisms: corticosteroid immunosuppression, cytarabine-induced DNA damage, vincristine-mediated microtubule disruption, and mercaptopurine purine antagonism.

This combination chemotherapy regimen suppresses leukemic cell proliferation through multiple mechanisms: corticosteroid immunosuppression, cytarabine-induced DNA damage, vincristine-mediated microtubule disruption, and mercaptopurine purine antagonism. Used for Acute lymphoblastic leukemia (ALL) in pediatric patients.

At a glance

Mechanism of action

Prednisone provides anti-inflammatory and immunosuppressive effects. Cytarabine is a cytidine analog that inhibits DNA synthesis. Vincristine is a vinca alkaloid that disrupts microtubule formation and mitotic spindle function. Mercaptopurine is a purine analog that interferes with nucleotide metabolism. Together, these agents target leukemic blasts through complementary cytotoxic and cell cycle-disrupting pathways.

Approved indications

• Acute lymphoblastic leukemia (ALL) in pediatric patients

Common side effects

• Myelosuppression (neutropenia, thrombocytopenia, anemia)
• Infection
• Mucositis
• Nausea and vomiting
• Peripheral neuropathy
• Hepatotoxicity
• Hyperglycemia

Key clinical trials

• Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
• A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
• Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
• Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) (PHASE3)
• LBL-2016 for Children or Adolescents in China (PHASE3)
• A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) (PHASE3)
• A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia (PHASE2)
• Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Prednisone+Cytarabine+vincristine+Mercaptopurine CI brief — competitive landscape report
• Prednisone+Cytarabine+vincristine+Mercaptopurine updates RSS · CI watch RSS
• Shanghai Children's Medical Center portfolio CI

Frequently asked questions about Prednisone+Cytarabine+vincristine+Mercaptopurine

Related

• Drug class: All Combination chemotherapy regimen drugs
• Manufacturer: Shanghai Children's Medical Center — full pipeline
• Therapeutic area: All drugs in Oncology
• Indication: Drugs for Acute lymphoblastic leukemia (ALL) in pediatric patients